CFO’s Tiny Tax‑Cover Sale at Amphastar Leaves Investors Unshaken as Share‑Buyback Expands

Insider Selling in a Resilient Pharma Stock Amphastar’s CFO, William J. Peters, sold 1,973 shares of common stock on March 15, 2026, a move that followed a flurry of other transactions from the same executive over the past week. The sale occurred at $18.18 per share, slightly below the market close of $19.41, and was reported as part of a tax‑liability settlement for vested restricted‑stock units. With the company’s share‑repurchase program recently expanded by $50 million, the sale is unlikely to add significant selling pressure; it is a routine event that aligns with the CFO’s need to settle tax obligations.

What It Means for Investors The volume of the trade—under 2,000 shares—represents a modest fraction of the 83‑million‑share outstanding market cap of $835 million. Even combined with the other insider sales from the week, the net selling remains small relative to the total float. Investors should therefore view the transaction as an administrative maneuver rather than a bearish signal. The company’s robust P/E ratio of 9.5, coupled with a 3.17 % weekly gain, suggests that the market remains confident in Amphastar’s drug portfolio and its ongoing repurchase strategy, which is designed to counteract dilution from employee equity.

Profile of William J. Peters Peters has been an active insider since at least December 2025, alternating between buying and selling shares and exercising options. In March 2026 alone, he sold a total of 7,317 shares across multiple filings (3,297 + 1,973 + 1,744 + 2,146 + 1,744) while also purchasing 58,693 shares and 121,071 option‑grant shares. His trading pattern indicates a balance between maintaining a substantial stake—currently over 180,000 shares—and managing liquidity needs, often triggered by vesting events. The recent tax‑related sale fits this historical behavior: a small, timely divestment to cover obligations without materially altering his ownership level.

Outlook for Amphastar Amphastar’s recent quarterly performance, coupled with a strong pipeline of generic and proprietary injectables, provides a solid foundation for long‑term growth. The CFO’s modest selling activity, framed by the company’s share‑repurchase expansion, is unlikely to disturb the upward trajectory. For investors, the key focus should remain on the company’s ability to deliver on its drug development milestones and to sustain shareholder value through disciplined capital allocation.